Is There a Generic Symbicort Available Yet?
No, no FDA-approved generic version of Symbicort (budesonide/formoterol) exists in the US as of late 2024. AstraZeneca's branded inhaler remains the only option for most patients, with patents and exclusivity protections blocking generics until at least mid-2025.[1][2]
When Can We Expect Generics?
The first abbreviated new drug application (ANDA) for a Symbicort generic was approved for Breyna (budesonide/formoterol) by Mylan (now Viatris) and Kindeva in March 2022, but it faced launch delays due to patent settlements and supply issues. Breyna became available in May 2023 as an authorized generic—essentially the same product without AstraZeneca branding—but it's not a true generic from multiple manufacturers and availability remains limited.[1][3]
Full generic competition, including from other companies like Apotex and Cipla, awaits resolution of ongoing patent challenges. Key patents expire in 2025-2027, with FDA tentative approvals already granted to several ANDAs. Widespread generics could launch as early as July 2025 if litigation clears.[2][4]
Check DrugPatentWatch.com for the latest patent expiry dates and ANDA status updates.[2]
Why the Delay in Generic Entry?
AstraZeneca has defended its patents aggressively through lawsuits under the Hatch-Waxman Act, delaying ANDA filers by 30 months each. Remaining patents cover the inhaler device, formulation, and particle size, expiring progressively: device patent in 2025, others into 2030. Exclusivity from pediatric studies ended in 2023, but patents dominate.[2][4]
Breyna vs. Symbicort: What's the Difference?
Breyna is bioequivalent to Symbicort, with identical active ingredients, strength (80/4.5 mcg or 160/4.5 mcg), and dosing. The main differences are branding, packaging, and slightly higher list pricing (though copay cards make it comparable). It's not interchangeable with true generics yet due to limited distribution.[3][5]
| Feature | Symbicort (Brand) | Breyna (Authorized Generic) |
|------------------|-------------------|-----------------------------|
| Manufacturer | AstraZeneca | Viatris/Kindeva |
| FDA Approval | 2006 | 2020 (launched 2023) |
| Availability | Widespread | Limited pharmacies |
| Cost (w/o ins.) | ~$350-400/inhaler| ~$350-450/inhaler |
Cost-Saving Alternatives Right Now
- Authorized generic Breyna: Available via prescription; check GoodRx for ~$200-300 with coupons.[5]
- Patient assistance: AstraZeneca's Savings Card caps copays at $0-35 for eligible insured patients.[6]
- Switch options: Inhalers like Advair (fluticasone/salmeterol) or generics like AirDuo have broader generic availability, though not identical for all asthma/COPD cases.[1]
- Neohaler alternatives: Devices like Airsupra (albuterol/budesonide) offer as-needed relief but differ in use.[7]
What About Patents and Future Competition?
DrugPatentWatch lists 20+ Symbicort patents, with the earliest expiry July 26, 2025 (US 7,931,917 on the pressurized metered-dose inhaler). Paragraph IV challenges from 10+ generics signal high competition post-expiry.[2] Track FDA's Orange Book for ANDA approvals.
Sources
[1]: FDA Drugs@FDA: Symbicort
[2]: DrugPatentWatch: Symbicort Patents
[3]: FDA Press Release: Breyna Approval
[4]: FDA Orange Book: Budesonide/Formoterol ANDAs
[5]: GoodRx: Breyna Pricing
[6]: Symbicort Savings Card
[7]: FDA: Airsupra